10-K Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 FY 2017

Filing Information

Form Type	10-K
Accession Number	`0001532176-18-000013`
Period End Date	20171231
Filing Date	20180208
Fiscal Year	2017
Fiscal Period	FY
XBRL Instance	regn-20171231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 78 Income Statement 115 Cash Flow Statement 97 Stockholders Equity 48

Balance Sheet 78 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$812.73M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$648.72M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$596.85M	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$503.48M	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.34B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.54B	USD	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$193.68M	USD	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$92.99M	USD	Point-in-time
Treasury stock, shares outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Treasury stock, shares outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$175.26M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$242.01M	USD	Point-in-time
Inventories	`InventoryNet`	$399.36M	USD	Point-in-time
Inventories	`InventoryNet`	$726.14M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$130.53M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$224.97M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.18B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.34B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$864.26M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$1.49B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.36B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.08B	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$825.30M	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$506.29M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$20.29M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$77.87M	USD	Point-in-time
Total assets	`Assets`	$8.76B	USD	Point-in-time
Total assets	`Assets`	$6.97B	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$815.08M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$879.10M	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationscurrent`	-	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationscurrent`	$129.56M	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$115.27M	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$177.75M	USD	Point-in-time
Deferred revenue - other, current portion	`DeferredRevenueExcludingAmountsFromRelatedPartyCurrent`	$142.39M	USD	Point-in-time
Deferred revenue - other, current portion	`DeferredRevenueExcludingAmountsFromRelatedPartyCurrent`	$116.40M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$267.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$1.18M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.24B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.14B	USD	Point-in-time
Capital and facility lease obligations, noncurrent	`Capitalandfacilityleaseobligationsnoncurrent`	$703.45M	USD	Point-in-time
Capital and facility lease obligations, noncurrent	`Capitalandfacilityleaseobligationsnoncurrent`	$351.57M	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$379.94M	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$503.47M	USD	Point-in-time
Deferred revenue - other	`DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent`	$327.30M	USD	Point-in-time
Deferred revenue - other	`DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent`	$249.26M	USD	Point-in-time
Other long term liabilities	`OtherLiabilitiesNoncurrent`	$100.39M	USD	Point-in-time
Other long term liabilities	`OtherLiabilitiesNoncurrent`	$152.07M	USD	Point-in-time
Total liabilities	`Liabilities`	$2.52B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.62B	USD	Point-in-time
Commitments and contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.51B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.03B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$2.95B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$1.75B	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$640.00K	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-12.84M	USD	Point-in-time
Treasury Stock	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Treasury Stock	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$4.45B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$2.55B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.14B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$3.65B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$8.76B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$6.97B	USD	Point-in-time

Income Statement 115 line items

Line Item	Tag	Value	Unit	Period
Net product sales	`SalesRevenueGoodsNet`	$3.72B	USD	Annual
Net product sales	`SalesRevenueGoodsNet`	$3.34B	USD	Annual
Net product sales	`SalesRevenueGoodsNet`	$2.69B	USD	Annual
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$658.66M	USD	Annual
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$877.19M	USD	Annual
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$758.87M	USD	Annual
Bayer collaboration revenue	`OtherCollaborationRevenue`	$938.05M	USD	Annual
Bayer collaboration revenue	`OtherCollaborationRevenue`	$580.49M	USD	Annual
Bayer collaboration revenue	`OtherCollaborationRevenue`	$744.27M	USD	Annual
Other revenue	`OtherSalesRevenueNet`	$74.89M	USD	Annual
Other revenue	`OtherSalesRevenueNet`	$338.52M	USD	Annual
Other revenue	`OtherSalesRevenueNet`	$119.10M	USD	Annual
Total revenues	`Revenues`	$1.50B	USD	1 Quarter
Total revenues	`Revenues`	$4.86B	USD	Annual
Total revenues	`Revenues`	$1.23B	USD	1 Quarter
Total revenues	`Revenues`	$1.58B	USD	1 Quarter
Total revenues	`Revenues`	$1.21B	USD	1 Quarter
Total revenues	`Revenues`	$4.10B	USD	Annual
Total revenues	`Revenues`	$1.47B	USD	1 Quarter
Total revenues	`Revenues`	$1.32B	USD	1 Quarter
Total revenues	`Revenues`	$1.20B	USD	1 Quarter
Total revenues	`Revenues`	$1.22B	USD	1 Quarter
Total revenues	`Revenues`	$5.87B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.05B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.08B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.62B	USD	Annual
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$838.53M	USD	Annual
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$1.18B	USD	Annual
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$1.32B	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$194.62M	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$241.70M	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$202.51M	USD	Annual
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$194.55M	USD	Annual
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$151.01M	USD	Annual
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$105.07M	USD	Annual
Total expenses	`CostsAndExpenses`	$3.79B	USD	Annual
Total expenses	`CostsAndExpenses`	$2.85B	USD	Annual
Total expenses	`CostsAndExpenses`	$3.53B	USD	Annual
Income from operations	`OperatingIncomeLoss`	$2.08B	USD	Annual
Income from operations	`OperatingIncomeLoss`	$1.33B	USD	Annual
Income from operations	`OperatingIncomeLoss`	$1.25B	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$24.04M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$6.27M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-12.58M	USD	Annual
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-14.24M	USD	Annual
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-25.12M	USD	Annual
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-7.20M	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$-926.00K	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$-1.08M	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$-26.82M	USD	Annual
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.33B	USD	Annual
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$2.08B	USD	Annual
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.23B	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$880.00M	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$434.29M	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$589.04M	USD	Annual
Net income	`NetIncomeLoss`	$387.74M	USD	1 Quarter
Net income	`NetIncomeLoss`	$388.32M	USD	1 Quarter
Net income	`NetIncomeLoss`	$264.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$248.93M	USD	1 Quarter
Net income	`NetIncomeLoss`	$196.22M	USD	1 Quarter
Net income	`NetIncomeLoss`	$181.38M	USD	1 Quarter
Net income	`NetIncomeLoss`	$895.52M	USD	Annual
Net income	`NetIncomeLoss`	$636.06M	USD	Annual
Net income	`NetIncomeLoss`	$1.20B	USD	Annual
Net income	`NetIncomeLoss`	$173.52M	USD	1 Quarter
Net income	`NetIncomeLoss`	$253.12M	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$3.64	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$11.27	USD	Annual
Net income per share - basic	`EarningsPerShareBasic`	$1.62	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$2.41	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$2.53	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$8.55	USD	Annual
Net income per share - basic	`EarningsPerShareBasic`	$2.36	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$3.66	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$1.74	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$1.88	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$6.17	USD	Annual
Net income per share - diluted	`EarningsPerShareDiluted`	$10.34	USD	Annual
Net income per share - diluted	`EarningsPerShareDiluted`	$1.50	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$7.70	USD	Annual
Net income per share - diluted	`EarningsPerShareDiluted`	$2.16	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$3.34	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$2.27	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$1.59	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$5.52	USD	Annual
Net income per share - diluted	`EarningsPerShareDiluted`	$3.32	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$2.19	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$1.69	USD	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	104.72M	shares	Annual
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	106.34M	shares	Annual
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	103.06M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.23M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	116.37M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.95M	shares	Annual
Net income	`NetIncomeLoss`	$387.74M	USD	1 Quarter
Net income	`NetIncomeLoss`	$388.32M	USD	1 Quarter
Net income	`NetIncomeLoss`	$264.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$248.93M	USD	1 Quarter
Net income	`NetIncomeLoss`	$196.22M	USD	1 Quarter
Net income	`NetIncomeLoss`	$181.38M	USD	1 Quarter
Net income	`NetIncomeLoss`	$895.52M	USD	Annual
Net income	`NetIncomeLoss`	$636.06M	USD	Annual
Net income	`NetIncomeLoss`	$1.20B	USD	Annual
Net income	`NetIncomeLoss`	$173.52M	USD	1 Quarter
Net income	`NetIncomeLoss`	$253.12M	USD	1 Quarter
Unrealized (loss) gain on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-43.68M	USD	Annual
Unrealized (loss) gain on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$12.71M	USD	Annual
Unrealized (loss) gain on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-21.41M	USD	Annual
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$765.00K	USD	Annual
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	-	USD	Annual
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	-	USD	Annual
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$1.21B	USD	Annual
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$874.11M	USD	Annual
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$592.38M	USD	Annual

Cash Flow Statement 97 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$387.74M	USD	1 Quarter
Net income	`NetIncomeLoss`	$388.32M	USD	1 Quarter
Net income	`NetIncomeLoss`	$264.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$248.93M	USD	1 Quarter
Net income	`NetIncomeLoss`	$196.22M	USD	1 Quarter
Net income	`NetIncomeLoss`	$181.38M	USD	1 Quarter
Net income	`NetIncomeLoss`	$895.52M	USD	Annual
Net income	`NetIncomeLoss`	$636.06M	USD	Annual
Net income	`NetIncomeLoss`	$1.20B	USD	Annual
Net income	`NetIncomeLoss`	$173.52M	USD	1 Quarter
Net income	`NetIncomeLoss`	$253.12M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$104.75M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$145.47M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$74.91M	USD	Annual
Non-cash compensation expense	`ShareBasedCompensation`	$459.05M	USD	Annual
Non-cash compensation expense	`ShareBasedCompensation`	$507.28M	USD	Annual
Non-cash compensation expense	`ShareBasedCompensation`	$559.88M	USD	Annual
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-63.58M	USD	Annual
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-45.14M	USD	Annual
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-52.56M	USD	Annual
Deferred Taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$360.08M	USD	Annual
Deferred Taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$-318.81M	USD	Annual
Deferred Taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$121.62M	USD	Annual
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$362.72M	USD	Annual
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$491.42M	USD	Annual
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$143.83M	USD	Annual
Increase in Inventories	`IncreaseDecreaseInInventories`	$314.19M	USD	Annual
Increase in Inventories	`IncreaseDecreaseInInventories`	$149.78M	USD	Annual
Increase in Inventories	`IncreaseDecreaseInInventories`	$111.83M	USD	Annual
(Increase) decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-23.54M	USD	Annual
(Increase) decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$113.33M	USD	Annual
(Increase) decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$79.48M	USD	Annual
(Decrease) increase in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-113.10M	USD	Annual
(Decrease) increase in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$244.27M	USD	Annual
(Decrease) increase in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$608.89M	USD	Annual
(Decrease) increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-23.19M	USD	Annual
(Decrease) increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$253.98M	USD	Annual
(Decrease) increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$303.66M	USD	Annual
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$694.72M	USD	Annual
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$108.60M	USD	Annual
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$577.87M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.33B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.47B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.31B	USD	Annual
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$557.11M	USD	Annual
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$809.42M	USD	Annual
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$1.28B	USD	Annual
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$544.58M	USD	Annual
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$327.44M	USD	Annual
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$274.46M	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$511.94M	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$272.63M	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$677.93M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.05B	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.01B	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-907.60M	USD	Annual
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$5.08M	USD	Annual
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$27.37M	USD	Annual
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$57.00M	USD	Annual
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebtAndCapitalSecurities`	$1.35M	USD	Annual
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebtAndCapitalSecurities`	$19.93M	USD	Annual
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebtAndCapitalSecurities`	$32.77M	USD	Annual
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	$166.47M	USD	Annual
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	$12.89M	USD	Annual
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	-	USD	Annual
Payments in connection with reduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	$573.49M	USD	Annual
Payments in connection with reduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	$643.37M	USD	Annual
Payments in connection with reduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	-	USD	Annual
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$206.36M	USD	Annual
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$240.21M	USD	Annual
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$126.74M	USD	Annual
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$301.69M	USD	Annual
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$160.54M	USD	Annual
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$143.18M	USD	Annual
Excess Tax Benefit from Share-based compensation	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	$405.32M	USD	Annual
Excess Tax Benefit from Share-based compensation	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	-	USD	Annual
Excess Tax Benefit from Share-based compensation	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	-	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-262.80M	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-700.39M	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-24.40M	USD	Annual
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-273.90M	USD	Annual
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$277.53M	USD	Annual
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$160.38M	USD	Annual
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$812.73M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$648.72M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$812.73M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$648.72M	USD	Point-in-time
Cash paid for interest (net of amounts capitalized)	`InterestPaidNet`	$10.58M	USD	Annual
Cash paid for interest (net of amounts capitalized)	`InterestPaidNet`	$18.68M	USD	Annual
Cash paid for interest (net of amounts capitalized)	`InterestPaidNet`	$5.45M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$481.36M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$276.09M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$754.84M	USD	Annual

Stockholders Equity 48 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$4.45B	USD	Point-in-time
Balance	`StockholdersEquity`	$2.55B	USD	Point-in-time
Balance	`StockholdersEquity`	$6.14B	USD	Point-in-time
Balance	`StockholdersEquity`	$3.65B	USD	Point-in-time
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$240.58M	USD	Annual
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$115.18M	USD	Annual
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$215.46M	USD	Annual
Common Stock tendered upon exercise of stock options in connection with employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$201.62M	USD	Annual
Common Stock tendered upon exercise of stock options in connection with employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$143.18M	USD	Annual
Common Stock tendered upon exercise of stock options in connection with employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$160.54M	USD	Annual
Adjustments related to tax withholding for share based compensation, restricted stock	`Adjustmentsrelatedtotaxwithholdingforsharebasedcompensationrestrictedstock`	$100.07M	USD	Annual
Issuance of Common Stock in connection with conversion of convertible senior notes	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$48.00M	USD	Annual
Issuance of Common Stock in connection with conversion of convertible senior notes	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$818.36M	USD	Annual
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$16.56M	USD	Annual
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$15.38M	USD	Annual
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$19.42M	USD	Annual
Issuance of restricted Common Stock under Long-Term Incentive Plan	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Issuance of restricted Common Stock under Long-Term Incentive Plan	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Issuance of restricted Common Stock under Long-Term Incentive Plan	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$524.53M	USD	Annual
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$464.02M	USD	Annual
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$574.89M	USD	Annual
Excess tax benefit from stock-based compensation	`AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet`	$405.32M	USD	Annual
Acquisition of Common Stock in connection with exercise of convertible note hedges	`TreasuryStockValueAcquiredCostMethod`	-	USD	Annual
Acquisition of Common Stock in connection with exercise of convertible note hedges	`TreasuryStockValueAcquiredCostMethod`	-	USD	Annual
Reduction of warrants	`AdjustmentsToAdditionalPaidInCapitalOther`	$-643.37M	USD	Annual
Reduction of warrants	`AdjustmentsToAdditionalPaidInCapitalOther`	$-449.46M	USD	Annual
Reclassification of warrant liability	`Maximumamountofwarrantpayable`	$-23.32M	USD	Annual
Reduction of equity component of convertible senior notes	`AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments`	$47.79M	USD	Annual
Reduction of equity component of convertible senior notes	`AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments`	$819.66M	USD	Annual
Net income	`NetIncomeLoss`	$387.74M	USD	1 Quarter
Net income	`NetIncomeLoss`	$388.32M	USD	1 Quarter
Net income	`NetIncomeLoss`	$264.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$248.93M	USD	1 Quarter
Net income	`NetIncomeLoss`	$196.22M	USD	1 Quarter
Net income	`NetIncomeLoss`	$181.38M	USD	1 Quarter
Net income	`NetIncomeLoss`	$895.52M	USD	Annual
Net income	`NetIncomeLoss`	$636.06M	USD	Annual
Net income	`NetIncomeLoss`	$1.20B	USD	Annual
Net income	`NetIncomeLoss`	$173.52M	USD	1 Quarter
Net income	`NetIncomeLoss`	$253.12M	USD	1 Quarter
Other Comprehensive Income (Loss), Net of Tax	`OtherComprehensiveIncomeLossNetOfTax`	$-43.68M	USD	Annual
Other Comprehensive Income (Loss), Net of Tax	`OtherComprehensiveIncomeLossNetOfTax`	$13.48M	USD	Annual
Other Comprehensive Income (Loss), Net of Tax	`OtherComprehensiveIncomeLossNetOfTax`	$-21.41M	USD	Annual
Balance	`StockholdersEquity`	$4.45B	USD	Point-in-time
Balance	`StockholdersEquity`	$2.55B	USD	Point-in-time
Balance	`StockholdersEquity`	$6.14B	USD	Point-in-time
Balance	`StockholdersEquity`	$3.65B	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.